PAX2 and nonpapillary renal cell carcinoma: Although these findings were somewhat unpredicted owing to the role ascribed to PAX2 as a transcription factor, our results are in agreement with those of Mazal et al., who also reported a decrease or lack of Pax-2 immunoexpression with increasing Fuhrman grade [23], and of Luu et al., although a different grading system was used and only ccRCC were analysed [32].